Reich Kristian 4

What Happened
Kristian Reich, Chief Scientific Officer of MoonLake Immunotherapeutics (MLTX), sold 43,700 ordinary shares on July 20, 2026. The shares were sold at a weighted-average price of $20.09 per share (range $20.00–$20.25), for total proceeds of approximately $877,933. The sales were executed pursuant to a Rule 10b5-1 trading plan adopted March 10, 2026.

Key Details

• Transaction date: July 20, 2026; Form 4 filed July 21, 2026 (within the standard two-business-day reporting window).
• Sale type / code: S (open-market sale executed under a 10b5-1 plan).
• Shares sold: 43,700; weighted-average price: $20.09; price range: $20.00–$20.25; proceeds ≈ $877,933.
• Shares owned after transaction: not disclosed in the provided filing excerpt.
• Footnotes of note:
  • F1: Transaction executed under a Rule 10b5-1 trading plan (adopted 3/10/2026).
  • F2: Reported price is a weighted average; shares sold in multiple transactions; issuer will provide per-price breakdown upon SEC staff request.
  • F3: Some shares are owned by JeruCON Beratungsgesellschaft mbH; Dr. Reich may be deemed an indirect beneficial owner of those shares under Section 16.

Context
Sales made under pre-established 10b5-1 plans are generally treated as pre-planned transactions and are often routine; they do not, by themselves, prove current insider sentiment. This filing is a routine insider sale and was reported in a timely Form 4.